Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)
The primary purpose of the study is to test the safety of HPV Vaccine in Women
Cervical Cancer|Genital Warts
BIOLOGICAL: V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years|BIOLOGICAL: Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years
Quadrivalent HPV vaccine is generally well tolerated when administered alone or concomitantly with hepatitis B vaccine.
HPV vaccine is well tolerated in 16-23 year old females.
The primary purpose of the study is to test the safety of HPV Vaccine in Women